Currently, Inovio Pharmaceuticals Inc [INO] is trading at $1.85, up 3.93%. An important factor to consider is whether the stock is rising or falling in short-term value. The INO shares have gain 4.52% over the last week, with a monthly amount drifted -3.65%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Inovio Pharmaceuticals Inc [NASDAQ: INO] stock has seen the most recent analyst activity on May 14, 2024, when Stephens initiated its Overweight rating and assigned the stock a price target of $20. Previously, Oppenheimer upgraded its rating to Outperform on January 25, 2024, and kept the price target unchanged to $4. On November 09, 2022, downgrade downgraded it’s rating to Hold. BofA Securities downgraded its rating to a Underperform but stick to its price target of $2 on November 01, 2022. Oppenheimer downgraded its rating to Perform for this stock on May 11, 2022. In a note dated January 21, 2022, BofA Securities upgraded an Neutral rating on this stock and boosted its target price from $8 to $10.
This stock has fluctuated between a low of $1.42 and a high of $13.44 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $22.67 within the next 12 months. Inovio Pharmaceuticals Inc [NASDAQ: INO] shares were valued at $1.85 at the most recent close of the market. An investor can expect a potential return of 1125.41% based on the average INO price forecast.
Analyzing the INO fundamentals
Trailing Twelve Months sales for Inovio Pharmaceuticals Inc [NASDAQ:INO] were 0.22M which represents 13.97% growth. Gross Profit Margin for this corporation currently stands at -6.29% with Operating Profit Margin at -516.17%, Pretax Profit Margin comes in at -115944.3%, and Net Profit Margin reading is -115944.3%. To continue investigating profitability, this company’s Return on Assets is posted at -223.04, Equity is -303.07 and Total Capital is -1.44. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.17.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.8000 points at the first support level, and at 1.7500 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.8800, and for the 2nd resistance point, it is at 1.9100.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Inovio Pharmaceuticals Inc [NASDAQ:INO] is 2.77. On the other hand, the Quick Ratio is 2.77, and the Cash Ratio is 1.86. Considering the valuation of this stock, the price to sales ratio is 308.40, the price to book ratio is 0.97.
